Research Highlight |
Featured
-
-
Research Highlight |
Disrupting a cell-specific miRNA–CXCR4 interaction is atheroprotective in mice
An approach that increases the expression of the chemokine receptor CXCR4 in vascular cells by targeting a microRNA-based repressive pathway attenuates atherosclerosis in mice and promotes atheroprotective functions in human and mouse vascular cells in vitro.
- Irene Fernández-Ruiz
-
Research Highlight |
Patisiran is beneficial for the treatment of TTR cardiac amyloidosis
Treatment with the small interfering RNA patisiran preserves functional capacity and improves health status and quality of life in patients with transthyretin cardiac amyloidosis, according to data from the 12-month double-blind period of the ongoing APOLLO-B trial.
- Irene Fernández-Ruiz
-
Research Highlight |
Promising novel siRNA for the treatment of hypertension
Patients with hypertension who receive a single subcutaneous dose of zilebesiran, a novel small-interfering RNA that inhibits hepatic angiotensinogen synthesis, have reductions in serum angiotensinogen levels and 24-h ambulatory blood pressure that last for up to 24 weeks, according to a phase I study.
- Irene Fernández-Ruiz
-
Research Highlight |
Promising findings for cell therapy in HFrEF
Findings from the DREAM-HF trial, the largest clinical trial of cell therapy in heart failure with reduced ejection fraction (HFrEF) to date, suggest that cardiac therapy with mesenchymal precursor cells might benefit patients with HFrEF, particularly those with inflammation.
- Irene Fernández-Ruiz
-
Research Highlight |
siRNA therapy markedly reduces Lp(a) levels
Olpasiran, a small interfering RNA (siRNA) that reduces lipoprotein(a) (Lp(a)) production in the liver, administered every 12 weeks induces a pronounced and sustained decrease in the plasma levels of Lp(a) in patients with established atherosclerotic cardiovascular disease, according to findings from the OCEAN(a)-DOSE trial.
- Irene Fernández-Ruiz
-
Research Highlight |
Selective JAG1–NOTCH3 targeting shows potential for treating PAH
Different Notch ligands have opposing roles in regulating the proliferation and differentiation of vascular smooth muscle cells in the pulmonary vasculature in pulmonary arterial hypertension. Selectively targeting Jagged 1–NOTCH3 signalling might be an effective and safe strategy for the treatment of this condition.
- Irene Fernández-Ruiz
-
-
-
Research Highlight |
Twice-yearly inclisiran injections halve LDL-cholesterol levels
The safety and durability of the LDL-cholesterol-lowering effects of inclisiran, a small interfering RNA that inhibits the synthesis of PCSK9 in the liver, have now been confirmed in three phase III clinical trials published in the New England Journal of Medicine.
- Irene Fernández-Ruiz
-
-
-
Review Article |
Abdominal aortic aneurysm: update on pathogenesis and medical treatments
This Review discusses the latest findings and current theories on the pathogenesis of abdominal aortic aneurysm (AAA) and highlights potential medical therapies for AAA, summarizing previous, ongoing, and potential clinical trials of medical interventions for small AAAs. This expanding volume of research is expected to result in a range of novel medical therapies for AAA within the next decade.
- Jonathan Golledge
-
Comment |
Hallmarks of cardiac regeneration
Despite substantial advances, bona fide regeneration of the damaged human heart is still an unmet ambition. By extracting our current knowledge from developmental biology, animal models of heart regeneration, and clinical observations, we propose five hallmarks of cardiac regeneration and suggest a holistic approach to reconstituting human heart function.
- Alessandro Bertero
- & Charles E. Murry
-
-
Review Article |
Therapeutic approaches for cardiac regeneration and repair
This Review discusses the advances in therapeutic approaches for cardiac repair and regeneration, including cell-based therapies as well as the use of secretory factors, such as microRNAs and exosomes, direct reprogramming strategies, and gene editing to control cardiac remodelling and redirect the adult heart to a regenerative state, and highlights the future prospects of preclinical and clinical trials of heart regeneration.
- Hisayuki Hashimoto
- , Eric N. Olson
- & Rhonda Bassel-Duby
-
Review Article |
Cell therapy trials for heart regeneration — lessons learned and future directions
The conflicting results of cell therapy clinical trials for heart regeneration have led to some confusion over the efficacy of this approach. This Review summarizes the main outcomes of these studies and gives perspectives for future cell-based regenerative trials largely based on the primary therapeutic target: regeneration of lost myocardium by exogenous cells or promotion of intrinsic repair though paracrine signalling.
- Philippe Menasché
-
-
-
-
-
-
-
Research Highlight |
Myocardial regeneration after infarction—promising phase I trial results
- Gregory B. Lim
-
-
-
-
Review Article |
Cell therapy for the treatment of coronary heart disease: a critical appraisal
Cell therapy could improve cardiac function in patients with coronary heart disease. In this article, the authors provide an overview of the clinical trials in this field and highlight the limitations of cardiac cell therapy. They also discuss how these issues are being addressed and what the future may hold for this therapy.
- Kai C. Wollert
- & Helmut Drexler
Browse broader subjects
Browse narrower subjects
- Antagomir and RNA sponge
- Antibody fragment therapy
- Antibody therapy
- Antisense oligonucleotide therapy
- Cell therapies
- DNA vaccines
- Gene therapy
- Locked nucleic acid
- Meganucleases
- Nucleic-acid therapeutics
- Peptide nucleic acid oligo
- Recombinant peptide therapy
- Recombinant protein therapy
- Recombinant vaccine
- RNA vaccines
- siRNAs
- TAL effector nuclease
- Triplex-forming oligonucleotide
- Zinc finger nuclease